CANCER THERAPY VIA A COMBINATION OF EPIGENETIC MODULATION AND IMMUNE MODULATION
First Claim
1. A method of treating or preventing a neoplastic condition in a subject in need thereof comprising administering (i) an epigenetic modulating agent and (ii) an immune modulating agent, thereby treating or preventing the neoplastic condition in the subject.
2 Assignments
0 Petitions
Accused Products
Abstract
Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
35 Citations
32 Claims
- 1. A method of treating or preventing a neoplastic condition in a subject in need thereof comprising administering (i) an epigenetic modulating agent and (ii) an immune modulating agent, thereby treating or preventing the neoplastic condition in the subject.
-
3. (canceled)
-
12. (canceled)
-
16. (canceled)
- 24. A method for selectively inhibiting the growth of a cell comprising contacting a cell with an amount of (i) an epigenetic modulating agent and (ii) an immune modulating agent sufficient to inhibit the growth of the cell.
-
26. (canceled)
-
30. (canceled)
-
31. A method for improving the anti-neoplastic effect of an immune modulating agent in a subject comprising administering an epigenetic modulating agent and the immune modulating agent to a subject, wherein said anti-neoplastic effect of the immune modulating agent in the subject is enhanced as compared to an appropriate control subject;
- or
a method of assessing the potential or realized anti-neoplastic effect of an epigenetic modulating agent and an immune modulating agent in a subject comprising measuring the expression of one or more genes selected from the group consisting of IRF7 and the genes of FIG. 25 , as a biomarker for the potential or realized anti-neoplastic effect of the epigenetic modulating agent and the immune modulating agent in the subject.
- or
-
32. (canceled)
Specification